Metabolic diseases with epilepsy

Metabolic diseases with epilepsy (Orphanet group code 166481) is not a single disease but rather a broad classification group encompassing a wide range of inherited metabolic disorders in which epilepsy (recurrent seizures) is a prominent clinical feature. This grouping includes dozens of distinct conditions where an underlying inborn error of metabolism leads to neurological dysfunction, with seizures being a key manifestation. Examples of conditions within this category include pyridoxine-dependent epilepsy, glucose transporter type 1 (GLUT1) deficiency syndrome, biotinidase deficiency, disorders of amino acid metabolism (such as nonketotic hyperglycinemia), organic acidurias, mitochondrial disorders (such as MERRF and MELAS), lysosomal storage diseases (such as neuronal ceroid lipofuscinoses), peroxisomal disorders, creatine deficiency syndromes, and disorders of purine and pyrimidine metabolism, among many others. The body systems most commonly affected include the central nervous system, with seizures often accompanied by developmental delay, intellectual disability, movement disorders, and progressive neurological deterioration. Many of these conditions also affect other organ systems including the liver, kidneys, heart, eyes, and skeletal muscle, depending on the specific metabolic pathway involved. Seizure types vary widely across the group and may include myoclonic, tonic-clonic, absence, infantile spasms, and other forms. Age of onset ranges from the neonatal period through adulthood, depending on the specific disorder. Treatment approaches vary considerably across the individual conditions within this group. Some metabolic epilepsies are highly treatable when identified early — for example, pyridoxine-dependent epilepsy responds to vitamin B6 supplementation, biotinidase deficiency responds to biotin, GLUT1 deficiency responds to a ketogenic diet, and cerebral folate deficiency responds to folinic acid. For many other conditions, treatment is primarily supportive, involving antiseizure medications, dietary management, cofactor supplementation, and multidisciplinary care. Early diagnosis through newborn screening, metabolic testing, and genetic analysis is critical, as timely intervention can significantly improve outcomes in treatable forms.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Metabolic diseases with epilepsy